Form 4: Acurx Pharmaceuticals Director Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Carl Sailer was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.
Summary
- Director Carl Sailer received a grant of 2,150 stock options on April 20, 2026.
- The options have an exercise price of $2.36 per share.
- The options are set to vest on April 20, 2027, and expire on April 20, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Minor dilution of existing shares upon the eventual exercise of these options.
Risks
- Market price volatility may impact the future value of the granted options.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure director retention and alignment with corporate performance milestones.
Comparison to Industry Standards
- The grant size and terms are consistent with standard director compensation policies for small-cap pharmaceutical companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of stock options pursuant to the Issuer's Director Compensation Policy. | 04/20/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minimal impact on shareholders due to the small number of options granted.
Next Steps
- Vesting of options on April 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/20/2026 | Date of grant for stock options |
| 04/20/2027 | Vesting date for the stock options |
| 04/20/2036 | Expiration date for the stock options |
Keywords
Acurx Pharmaceuticals, ACXP, Form 4, Director Compensation, Stock Options, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.